Transcription factor EB: A potential integrated network regulator in metabolic-associated cardiac injury

Area of Science:

• Cardiovascular Biology
• Metabolic Disease Pathophysiology
• Molecular Biology

Background:

• Cardiometabolic disease (CMD) is a major cause of mortality globally, driven by metabolic disorders like obesity and diabetes.
• The precise mechanisms of metabolic-associated cardiac injury remain unclear, necessitating novel therapeutic targets.
• Key metabolic disturbances include insulin resistance, hyperglycemia, hyperlipidemia, and cellular stresses.

Purpose of the Study:

• To review the multifaceted roles of Transcription Factor EB (TFEB) in metabolic regulation.
• To explore the relationship between TFEB and various pathophysiological processes implicated in CMD.
• To summarize TFEB's potential as a therapeutic target for cardiometabolic disease.

Main Methods:

• Literature review focusing on TFEB's function in metabolic pathways.
• Analysis of TFEB's involvement in insulin resistance, lipid metabolism, and cellular stress.
• Examination of TFEB's role in autophagy and mitochondrial quality control.

Main Results:

• TFEB regulates lysosomal biogenesis and autophagy, crucial for cellular homeostasis.
• Emerging evidence links TFEB to glucose and lipid metabolism regulation.
• TFEB influences pathways involved in oxidative stress, inflammation, and endoplasmic reticulum stress.

Conclusions:

• TFEB is implicated in multiple cellular processes disrupted in metabolic disorders.
• TFEB's regulatory functions suggest its involvement in the development of CMD.
• TFEB represents a promising novel therapeutic target for treating cardiometabolic disease.